Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

CEO Richard Miller emphasized promising Phase 1 trial results for soquelitinib in patients with atopic dermatitis ... to existing treatments like Dupixent and JAK inhibitors.

The key secondary endpoints (also assessed at 24 weeks) included change from baseline in itch and hives (weekly ... in people with atopic dermatitis and asthma who receive DUPIXENT.

might make atopic dermatitis symptoms significantly better in approximately 58% of patients, compared to just 15% with twice-weekly bathing. Although showers have not been well studied ...

The mechanism of action sets temtokibart apart from established eczema drugs such as Sanofi and Regeneron’s blockbuster immunology med Dupixent ... to severe atopic dermatitis, the most common ...

Galderma is now facing off against big, established rivals such as Sanofi and Regeneron’s Dupixent for the U.S. atopic dermatitis market ... was at about 30% weekly prurigo nodularis market ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...